公开(公告)号：EP2509991A2

公开(公告)日：2012-10-17

申请号：EP10836656.8

申请日：2010-12-08

申请人： Nitto Denko Corporation ,  Quark Pharmaceuticals, Inc.

发明人： JIN, Xiaomei ,  YU, Lei ,  TAKAHASHI, Hirokazu ,  TANAKA, Yasunobu ,  NIITSU, Yoshiro ,  FEINSTEIN, Elena ,  AVKIN-NACHUM, Sharon ,  KALINSKI, Hagar ,  METT, Igor ,  ERLICH, Shai ,  SQUIERS, Elizabeth, C. ,  CHEN, Ning

IPC分类号： C07H21/00 ,  A61K31/7088

CPC分类号： C12N15/113 ,  A61K31/713 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/31 ,  C12N2310/315 ,  C12N2310/317 ,  C12N2310/32 ,  C12N2310/321 ,  C12N2310/33 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2310/3521

摘要： Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.

公开(公告)号：EP2585594B1

公开(公告)日：2017-05-31

申请号：EP11728750.8

申请日：2011-06-23

申请人： Quark Pharmaceuticals, Inc.

发明人： AVKIN-NACHUM, Sharon ,  FEINSTEIN, Elena ,  KALINSKI, Hagar ,  METT, Igor

IPC分类号： C12N15/113 ,  A61K31/713

CPC分类号： C12N15/1135 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/321 ,  C12Q1/6888

公开(公告)号：EP2504435A1

公开(公告)日：2012-10-03

申请号：EP10785571.0

申请日：2010-11-25

申请人： Quark Pharmaceuticals, Inc.

发明人： AVKIN-NACHUM, Sharon

IPC分类号： C12N15/113 ,  A61K31/713

摘要： The invention relates to modified siRNA compounds which down-regulate target gene expression, to pharmaceutical compositions comprising such compounds and to methods of treating and/or preventing the incidence or severity of various diseases or conditions associated with the genes and/or symptoms associated with such diseases or conditions.

摘要翻译： 本发明涉及下调靶基因表达的修饰的siRNA化合物，包含这些化合物的药物组合物以及治疗和/或预防与这些化合物相关的基因和/或症状相关的各种疾病或病症的发生或严重性的方法 疾病或病症。

公开(公告)号：EP2681314B1

公开(公告)日：2017-11-01

申请号：EP12708474.7

申请日：2012-03-01

申请人： Quark Pharmaceuticals, Inc. ,  Washington University

发明人： GELMAN, Andrew E. ,  FEINSTEIN, Elena ,  ADAMSKY, Svetlana ,  METT, Igor ,  KALINSKI, Hagar ,  AVKIN-NACHUM, Sharon

IPC分类号： C12N15/113 ,  A61K31/713

CPC分类号： C12N15/113 ,  A61K31/713 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/344 ,  C12N2310/3521

摘要： Disclosed herein are therapeutic methods for treating lung diseases, disorders and injury in a mammal, including treatment of acute respiratory distress syndrome (ARDS), acute lung injury, pulmonary fibrosis (idiopathic), bleomycin induced pulmonary fibrosis, mechanical ventilator induced lung injury, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiolitis obliterans after lung transplantation and lung transplantation-induced acute graft dysfunction, including treatment, prevention or prevention of progression of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, bronchiolitis obliterans after lung transplantation and/or primary graft dysfunction (PGD) after organ transplantation, in particular in lung transplantation, comprising downregulating the TLR2 gene or both the TLR2 gene and TLR4 gene. Provided herein are compositions, methods and kits for treating lung diseases, disorders and injury.

公开(公告)号：EP2521783B1

公开(公告)日：2017-08-09

申请号：EP11701706.1

申请日：2011-01-06

申请人： Quark Pharmaceuticals, Inc.

发明人： AVKIN-NACHUM, Sharon ,  FEINSTEIN, Elena

IPC分类号： C12N15/113

CPC分类号： C12N15/113 ,  A61K31/713 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/317 ,  C12N2310/321 ,  C12N2310/332 ,  C12N2310/344 ,  C12N2310/351 ,  C12N2310/3527

公开(公告)号：EP2895608A1

公开(公告)日：2015-07-22

申请号：EP13776599.6

申请日：2013-09-12

申请人： Quark Pharmaceuticals, Inc.

发明人： FEINSTEIN, Elena ,  AVKIN-NACHUM, Sharon ,  KALINSKI, Hagar ,  METT, Igor

IPC分类号： C12N15/113 ,  A61K31/713

CPC分类号： C12N15/113 ,  C12N15/1135 ,  C12N15/1136 ,  C12N2310/14 ,  C12N2310/317 ,  C12N2310/319 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2320/30

摘要： The present application relates to nucleic acid compounds, compositions comprising same and methods of use thereof for treatment of various diseases, disorders and conditions. The compounds are preferably chemically synthesized and modified double-stranded nucleic acid molecules which down regulate expression of a p53 gene.

公开(公告)号：EP2739637A1

公开(公告)日：2014-06-11

申请号：EP12819429.7

申请日：2012-08-03

申请人： Quark Pharmaceuticals, Inc.

发明人： FEINSTEIN, Elena ,  AVKIN-NACHUM, Sharon ,  METT, Igor ,  KALINSKI, Hagar

IPC分类号： C07H21/00 ,  C12N15/113 ,  A61K31/7088

CPC分类号： C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/332 ,  C12N2310/333 ,  C12N2310/3341 ,  C12N2310/335 ,  C12N2310/336 ,  C12N2310/337 ,  C12N2310/3521 ,  C12N2310/50

摘要： The present application relates to double stranded nucleic acid compounds, compositions comprising same and methods of use thereof for the treatment of hearing loss in a subject in need thereof. The compounds are preferably chemically synthesized and modified dsRNA molecules which inhibit expression of a gene expressed selected from the group consisting of HES1, HES5, HEY1, HEY2, ID1, ID2, ID3, CDKN1B, and NOTCHl.

公开(公告)号：EP2585594A1

公开(公告)日：2013-05-01

申请号：EP11728750.8

申请日：2011-06-23

申请人： Quark Pharmaceuticals, Inc.

发明人： AVKIN-NACHUM, Sharon ,  FEINSTEIN, Elena ,  KALINSKI, Hagar ,  METT, Igor

IPC分类号： C12N15/113 ,  A61K31/713

CPC分类号： C12N15/1135 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/321 ,  C12Q1/6888

摘要： The present invention relates to compounds, pharmaceutical compositions comprising same, methods of use thereof and kits for the down-regulation of RhoA gene. The compounds, compositions, methods and kits are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated with diseases or conditions in which RhoA expression has adverse consequences and for conferring neuroprotection.

公开(公告)号：EP2504435B1

公开(公告)日：2019-11-13

申请号：EP10785571.0

申请日：2010-11-25

申请人： Quark Pharmaceuticals, Inc.

发明人： AVKIN-NACHUM, Sharon

IPC分类号： C12N15/113 ,  A61K31/713

公开(公告)号：EP2895607A2

公开(公告)日：2015-07-22

申请号：EP13773450.5

申请日：2013-09-12

申请人： Quark Pharmaceuticals, Inc.

发明人： FEINSTEIN, Elena ,  AVKIN-NACHUM, Sharon ,  KALINSKI, Hagar ,  METT, Igor

IPC分类号： C12N15/113 ,  A61K31/713

CPC分类号： C12N15/113 ,  C12N15/1135 ,  C12N15/1136 ,  C12N2310/14 ,  C12N2310/317 ,  C12N2310/319 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2320/30

摘要： The present application relates to nucleic acid compounds, compositions comprising same and methods of use thereof for treatment of various diseases, disorders and conditions. The compounds are preferably chemically synthesized and modified double-stranded nucleic acid molecules which down regulate expression of a p53 gene.